[go: up one dir, main page]

ES2116801T3 - Empleo de derivados de adamantano para el tratamiento de tinnitus. - Google Patents

Empleo de derivados de adamantano para el tratamiento de tinnitus.

Info

Publication number
ES2116801T3
ES2116801T3 ES96112325T ES96112325T ES2116801T3 ES 2116801 T3 ES2116801 T3 ES 2116801T3 ES 96112325 T ES96112325 T ES 96112325T ES 96112325 T ES96112325 T ES 96112325T ES 2116801 T3 ES2116801 T3 ES 2116801T3
Authority
ES
Spain
Prior art keywords
tinnitus
treatment
adamantane derivatives
alkyl
adamantane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96112325T
Other languages
English (en)
Inventor
Hans Peter Prof Dr Med Zenner
J Peter Prof Dr Ruppersberg
Andreas Dr Busch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TINNITUS FORSCHUNGS und ENTWIC
Original Assignee
TINNITUS FORSCHUNGS und ENTWIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TINNITUS FORSCHUNGS und ENTWIC filed Critical TINNITUS FORSCHUNGS und ENTWIC
Application granted granted Critical
Publication of ES2116801T3 publication Critical patent/ES2116801T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

UTILIZACION DE DERIVADOS DEL ADAMANTANO DE FORMULA EN DONDE R{SUB,1} Y R{SUB,2} SON - IGUALES O DIFERENTES Y PUEDEN SER HIDROGENO O GRUPOS ALQUILO DE CADENA LINEAL O RAMIFICADA CON 1 A 6 ATOMOS DE C, O - FORMAR JUNTO CON EL ATOMO DE N UN HETEROCICLO CON 5 O 6 ATOMOS, R{SUB,3} Y R{SUB,4} SON, IGUALES O DIFERENTES, HIDROGENO, GRUPOS ALQUILO DE CADENA LINEAL O RAMIFICADA CON 1 A 6 ATOMOS DE C, GRUPOS CICLOALQUILO CON 5 O 6 ATOMOS DE C, O EL GRUPO FENILO, Y EN DONDE R{SUB,5} PUEDE SER HIDROGENO O UN GRUPO ALQUILO DE CADENA LINEAL O RAMIFICADA CON 1 A 6 ATOMOS DE C; PARA EL TRATAMIENTO DE ENFERMEDADES DEL OIDO INTERNO.
ES96112325T 1995-08-02 1996-07-31 Empleo de derivados de adamantano para el tratamiento de tinnitus. Expired - Lifetime ES2116801T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19528388A DE19528388A1 (de) 1995-08-02 1995-08-02 Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs

Publications (1)

Publication Number Publication Date
ES2116801T3 true ES2116801T3 (es) 1998-07-16

Family

ID=7768513

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96112325T Expired - Lifetime ES2116801T3 (es) 1995-08-02 1996-07-31 Empleo de derivados de adamantano para el tratamiento de tinnitus.

Country Status (14)

Country Link
US (1) US6066652A (es)
EP (2) EP0834310A1 (es)
JP (1) JP3568039B2 (es)
KR (1) KR100393296B1 (es)
CN (1) CN1142775C (es)
AT (1) ATE163545T1 (es)
AU (1) AU719018B2 (es)
BR (1) BR9609950A (es)
DE (3) DE19528388A1 (es)
DK (1) DK0759295T3 (es)
ES (1) ES2116801T3 (es)
IL (1) IL123142A (es)
PL (1) PL324795A1 (es)
WO (1) WO1997004762A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649621B2 (en) * 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
DE19807426A1 (de) * 1998-02-23 1999-10-14 Otogene Biotechnologische Fors Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs
US7132406B2 (en) * 1998-02-23 2006-11-07 Sound Pharmaceuticals Incorporated Stimulation of cellular regeneration and differentiation in the inner ear
AU5170400A (en) 1999-05-27 2000-12-18 George F. El Khoury Topical application of muscarinic and opioid agents for treatment of tinnitus
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
DE60131010T2 (de) * 2000-08-08 2008-07-17 Evergreen Packaging International B.V. Verfahren zum aktivieren von sauerstoff entfernenden komponenten während eines verfahrens zum füllen von giebelbehältern
EP1190711A1 (en) * 2000-09-21 2002-03-27 Tinnitus Forschungs- und Entwicklungs GmbH Treatment of diseases with adamantane derivatives
EP1201234A3 (en) * 2000-09-21 2003-03-12 Tinnitus Forschungs- und Entwicklungs GmbH Treatment of diseases with adamantane derivates
EP1190709A1 (en) * 2000-09-21 2002-03-27 Tinnitus Forschungs- und Entwicklungs GmbH Treatment of tinnitus
TWI266614B (en) 2000-10-13 2006-11-21 Chugai Pharmaceutical Co Ltd Compositions comprising valine for improving lipid metabolism
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US7795468B2 (en) * 2001-01-19 2010-09-14 Chevron U.S.A. Inc. Functionalized higher diamondoids
US20030191064A1 (en) * 2001-01-23 2003-10-09 Kopke Richard D. Methods for preventing and treating loss of balance function due to oxidative stress
CA2497867A1 (en) * 2002-09-06 2004-03-18 Durect Corporation Delivery of modulators of glutamate-mediated neurotransmission to the inner ear
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) * 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8349359B2 (en) 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060211650A1 (en) * 2004-12-16 2006-09-21 Forest Laboratories, Inc. Reducing carbohydrate derivatives of adamantane amines, and synthesis and methods of use thereof
EP1861161A4 (en) * 2005-01-24 2012-05-16 Neurosystec Corp APPARATUS AND METHOD FOR DISPENSING THERAPEUTIC AND / OR OTHER AGENTS IN THE INTERNAL EAR AND OTHER FABRICS
DE102005004343A1 (de) * 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
US20060205789A1 (en) * 2005-03-04 2006-09-14 Neurosystec Corporation Gacyclidine formulations
BRPI0607017B8 (pt) 2005-04-06 2021-05-25 Adamas Pharmaceuticals Inc composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
WO2007012064A2 (en) * 2005-07-20 2007-01-25 Cypress Bioscience, Inc. Prevention and treatment of hearing disorders
KR101271263B1 (ko) 2005-09-28 2013-06-07 아우리스 메디칼 아게 내이 장애 치료용 약학 조성물
US8267905B2 (en) * 2006-05-01 2012-09-18 Neurosystec Corporation Apparatus and method for delivery of therapeutic and other types of agents
US7803148B2 (en) * 2006-06-09 2010-09-28 Neurosystec Corporation Flow-induced delivery from a drug mass
EP2046437A2 (en) * 2006-07-20 2009-04-15 Neurosystec Corporation Devices, systems and methods for ophthalmic drug delivery
JP2010511595A (ja) * 2006-07-31 2010-04-15 ニューロシステック コーポレイション 遊離塩基ガシクリジンナノ粒子
US20080065002A1 (en) * 2006-09-07 2008-03-13 Neurosystec Corporation Catheter for Localized Drug Delivery and/or Electrical Stimulation
US20100129467A9 (en) * 2007-08-31 2010-05-27 Albritton Iv Ford D Nutritional supplement
ES2596262T3 (es) * 2007-09-12 2017-01-05 Merz Pharma Gmbh & Co. Kgaa Derivados de 1-amino-alquilciclohexano para su uso en el tratamiento de tinnitus asociado con pérdida de audición
TW201010691A (en) * 2008-06-12 2010-03-16 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
US8454877B2 (en) * 2009-04-03 2013-06-04 Pelican Products, Inc. Method and apparatus for molding an article
CN106389381A (zh) 2009-12-02 2017-02-15 阿达玛斯医药公司 金刚烷胺组合物及其使用方法
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
ES2862673T3 (es) 2011-12-12 2021-10-07 Zilentin AG Tratamiento del tinnitus mediante la modulación del cotransportador de cloruro NKCC1 en el sistema auditivo
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
JP6657392B2 (ja) 2015-10-02 2020-03-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3328251A (en) * 1965-12-30 1967-06-27 Du Pont Pharmaceutical compositions and methods utilizing 2-aminoadamantane and its derivatives
US4331686A (en) * 1981-08-28 1982-05-25 Pennwalt Corporation Treatment of otitis externa in dogs with beta-(1-adamantyl)-alpha,alpha-dimethylethylamine
ES2059602T3 (es) * 1989-04-14 1994-11-16 Merz & Co Gmbh & Co Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral.
DE3921062A1 (de) * 1989-06-23 1991-01-03 Lange Werner Therapie und prophylaxe von infektionen mit retroviren mit 1-adamantanamin hydrochlorid (amantadin) allein oder in kombination mit anderen antiviralen substanzen
DE4014672A1 (de) * 1990-05-08 1991-11-14 Werner E G Prof Dr Mueller Verwendung von adamantan-derivaten zur zytoprotektion von nicht-infizierten und virus-infizierten lymphozyten als auch anderen zelltypen

Also Published As

Publication number Publication date
KR19990036073A (ko) 1999-05-25
JP3568039B2 (ja) 2004-09-22
DE59600105D1 (de) 1998-04-09
ATE163545T1 (de) 1998-03-15
MX9800925A (es) 1998-10-31
CN1194581A (zh) 1998-09-30
KR100393296B1 (ko) 2003-11-17
CN1142775C (zh) 2004-03-24
DE19680619D2 (de) 1998-10-29
AU719018B2 (en) 2000-05-04
IL123142A0 (en) 1998-09-24
PL324795A1 (en) 1998-06-22
DK0759295T3 (da) 1999-01-25
AU6788296A (en) 1997-02-26
EP0759295A1 (de) 1997-02-26
WO1997004762A1 (de) 1997-02-13
US6066652A (en) 2000-05-23
IL123142A (en) 2001-10-31
BR9609950A (pt) 1999-06-29
DE19528388A1 (de) 1997-02-06
JP2000515486A (ja) 2000-11-21
EP0834310A1 (de) 1998-04-08
EP0759295B1 (de) 1998-03-04

Similar Documents

Publication Publication Date Title
ES2116801T3 (es) Empleo de derivados de adamantano para el tratamiento de tinnitus.
ATE153240T1 (de) Behandlung peri-menopausaler syndrome
DE69426331D1 (de) Arzneimittel gegen nervöse erkrankungen
ES2106573T3 (es) Composicion oftalmica que contiene un derivado de 1,5-benzoxatiepina para tratar glaucoma.
ES2181853T3 (es) Tratamiento del tinnitus empleando agentes neuroprotectores.
NO305174B1 (no) Heterocykliske forbindelser
NO943521D0 (no) Anvendelse av et pyrrolidinacetamidderivat for fremstilling av et terapeutikum
PT655243E (pt) Derivados da melatonina para utilizacao no tratamento de disturbios do sono
CO4410336A1 (es) Derivados de quinoxalina utiles en terapia
DE69603667D1 (de) Indol-, Indazol- und Benzisoxazolderivate zur Behandlung von Schizophrenia
DK0604186T3 (da) HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
NO971743L (no) Farmasöytisk sammensetning for profylakse og behandling av type I allergiske sykdommer
ES2094545T3 (es) Derivados n-substituidos del 3-azabiciclo(3.2.0)heptano, como neurolepticos etc..
PT1068184E (pt) Derivados n-ariloxietilamina para o tratamento de depressao
ES2053612T3 (es) Agentes para la proteccion contra enfermedades de las plantas.
DE69619088D1 (de) Quinoxalin-Derivate zur Behandlung von Tinnitus
MX9306879A (es) Derivados de piperazina y composiciones farmaceuticas que los contienen,para el tratamiento de enfermedades del conocimiento.
ATE186912T1 (de) Carbamoylpyrrolidon-derivate zur behandlung von depressionen und cerebrovasculären störungen
DK0667860T3 (da) Azaspiroalkan-derivater som terapeutiske midler
TH18470A (th) อนุพันธ์เมลาโทนินสำหรับใช้ในการรักษาความผิดปกติของการหลับ
CO4290357A1 (es) Derivados de la cefalosporina, preparaciones farmaceuticas que las contienen y procedimiento para su preparacion y em- pleo.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 759295

Country of ref document: ES